Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Abstract

Lenalidomide is clinically active as first-line CLL therapy and is well-tolerated if a conservative approach with slow dose escalation is used. A lenalidomide-induced molecular signature provides insights into its immunomodulatory mechanisms of action in CLL.